Related Experiment Video
Updated: Mar 31, 2026

Endothelin-1 Induced Middle Cerebral Artery Occlusion Model for Ischemic Stroke with Laser Doppler Flowmetry Guidance in Rat
Published on: February 16, 2013
Low ADAMTS13 activity is associated with an increased risk of ischemic stroke
Michelle A H Sonneveld1, Moniek P M de Maat2, Marileen L P Portegies3
1Department of Hematology, Department of Neurology, and.
Abstract:
ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin motif repeats 13) has antithrombotic properties because it cleaves von Willebrand factor (VWF) in smaller, less active multimers. The aim of our study was to investigate prospectively the association between ADAMTS13 activity and ischemic stroke. We included 5941 individuals ≥55 years without a history of stroke or transient ischemic attack (TIA) of the Rotterdam Study, a population-based cohort study. ADAMTS13 activity was measured at inclusion with the FRETS-VWF73 assay and VWF antigen (VWF:Ag) levels by enzyme-linked immunosorbent assay. We assessed the association among ADAMTS13 activity, VWF:Ag levels, and ischemic stroke by Cox proportional hazard analysis. The added value of ADAMTS13 activity above the traditional risk factors for ischemic stroke risk prediction was examined by the C-statistic and the net reclassification improvement index (NRI). All individuals were followed for incident stroke or TIA. Over a median follow-up time of 10.7 years (56,403 total person-years), 461 participants had a stroke, 306 of which were ischemic. After adjustment for cardiovascular risk factors, individuals with ADAMTS13 activity in the lowest quartile had a higher risk of ischemic stroke (absolute risk, 7.3%) than did those in the reference highest quartile (absolute risk, 3.8%; hazard ratio, 1.65; 95% confidence interval [CI], 1.16-2.32). Adding ADAMTS13 to the model in prediction of ischemic stroke, increased the C-statistic by 0.013 (P = .003) and provided 0.058 (95% CI, -0.002 to 0.119) NRI. Low ADAMTS13 activity is associated with the risk of ischemic stroke and improves the accuracy of risk predictions for ischemic stroke beyond traditional risk factors.
Insights
Low ADAMTS13 activity increases ischemic stroke risk. Measuring ADAMTS13 activity improves stroke risk prediction beyond traditional factors.
Area of Science:
- Cardiovascular Medicine
- Hematology
Background:
- ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin motif repeats 13) cleaves von Willebrand factor (VWF), reducing its activity and possessing antithrombotic properties.
- Understanding the role of ADAMTS13 in cerebrovascular diseases like ischemic stroke is crucial for risk stratification.
Purpose of the Study:
- To prospectively investigate the association between ADAMTS13 activity and the risk of incident ischemic stroke.
- To evaluate the added value of ADAMTS13 activity in predicting ischemic stroke risk compared to established cardiovascular risk factors.
Main Methods:
- A prospective population-based cohort study (Rotterdam Study) including 5941 individuals aged ≥55 years without prior stroke or TIA.
- ADAMTS13 activity and VWF antigen (VWF:Ag) levels were measured at baseline.
- Cox proportional hazard analysis and reclassification metrics (C-statistic, NRI) were used to assess associations and predictive value over a median follow-up of 10.7 years.
Main Results:
- Individuals in the lowest quartile of ADAMTS13 activity had a significantly higher risk of ischemic stroke (HR, 1.65; 95% CI, 1.16-2.32) compared to the highest quartile, after adjusting for cardiovascular risk factors.
- Incorporating ADAMTS13 activity into risk prediction models significantly improved stroke prediction accuracy, evidenced by an increase in the C-statistic and NRI.
Conclusions:
- Low ADAMTS13 activity is an independent risk factor associated with an increased risk of ischemic stroke.
- Assessing ADAMTS13 activity can enhance the prediction of ischemic stroke risk beyond traditional risk factors, potentially aiding in primary prevention strategies.
Related Concept Videos
Atherosclerosis III: Management
Acute Coronary Syndrome III: Diagnostic Studies
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

